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have previously shown that chenodeoxycholic acid (CDCA) strongly
inhibits pancreatic ductal HCO3 secretion through the destruction of
mitochondrial function, which may have significance in the patho-
mechanism of acute pancreatitis (AP). Ursodeoxycholic acid (UDCA)
is known to protect the mitochondria against hydrophobic bile acids
and has an ameliorating effect on cell death. Therefore, our aim was
to investigate the effect of UDCA pretreatment on CDCA-induced
pancreatic ductal injury. Guinea pig intrainterlobular pancreatic ducts
were isolated by collagenase digestion. Ducts were treated with
UDCA for 5 and 24 h, and the effect of CDCA on intracellular Ca2
concentration ([Ca2]i), intracellular pH (pHi), morphological and
functional changes of mitochondria, and the rate of apoptosis were
investigated. AP was induced in rat by retrograde intraductal injection
of CDCA (0.5%), and the disease severity of pancreatitis was assessed
by measuring standard laboratory and histological parameters. Twen-
ty-four-hour pretreatment of pancreatic ducts with 0.5 mM UDCA
significantly reduced the rate of ATP depletion, mitochondrial injury,
and cell death induced by 1 mM CDCA and completely prevented the
inhibitory effect of CDCA on acid-base transporters. UDCA pretreat-
ment had no effect on CDCA-induced Ca2 signaling. Oral admin-
istration of UDCA (250 mg/kg) markedly reduced the severity of
CDCA-induced AP. Our results clearly demonstrate that UDCA 1)
suppresses the CDCA-induced pancreatic ductal injury by reducing
apoptosis and mitochondrial damage and 2) reduces the severity of
CDCA-induced AP. The protective effect of UDCA against hydro-
phobic bile acids may represent a novel therapeutic target in the
treatment of biliary AP.
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ACUTE PANCREATITIS (AP) IS a sudden and severe disease in which
no specific therapy or medication is currently available. Ob-
struction of the common biliopancreatic duct by a gallstone is
a frequent cause of AP however, the exact mechanism is not
completely known (1, 34). A number of theories have been
proposed to explain how gallstones cause pancreatitis. One of
the most accepted views is that bile reflux into the pancreatic
ductal system leads to AP. This “bile reflux” theory is largely
based on animal studies where retrograde infusion of bile acids
into the pancreatic duct triggers pancreatitis (33, 35, 64).
Therefore, the cytotoxic effects of bile acids have been widely
investigated in the pancreas (15, 23, 59, 61). Initial studies, in
which the main pancreatic duct was perfused with various bile
acids, demonstrated that in the millimolar range, hydrophobic
bile acids cause mucosal damage and increase the permeability
of the pancreatic ducts to different ions (12, 39).
The cytotoxic effect of chenodeoxycholic acid (CDCA) is
basically attributed to its detergent characteristic, which is
responsible for the disruption of the membrane integrity and
consequently the release of intracellular constituents. However,
an increasing number of studies suggest that nondetergent
effects of bile acids are also involved in the bile-induced
cellular injury. The monohydroxy bile acid, taurolithocholic
acid-3-sulfate (TLC-S) causes acinar injury through the induc-
tion of long-term elevation of intracellular calcium concentra-
tion ([Ca2]i), mitochondrial membrane depolarization, and
consequently intracellular ATP (ATPi) depletion.(15, 61, 63).
The specific effects of bile acids have been also demon-
strated in the pancreatic ductal epithelial cells (PDECs). Recent
studies from our laboratory showed that the dihydroxy bile
acid, CDCA, dose dependently decreased the intracellular pH
(pHi) and caused elevation of [Ca2]i in guinea pig pancreatic
ducts (59). In addition, we showed that high concentration of
this bile acid (1 mM) strongly inhibited both oxidative and
glycolytic metabolism of the ductal cells and caused an irre-
versible depletion of ATPi (29) Moreover, it has been recently
demonstrated that CDCA induces ATP release from both
ductal and acinar cells, which probably play a role in the
CDCA-induced [Ca2]i elevation by the activation of P2 re-
ceptors (24). In the absence of ATPi, the acid/base transporters
fail to function properly, which finally causes decreased fluid and
HCO3 secretion (29). Impaired fluid secretion can lead to pan-
creatic injury and likely contributes to the development of pan-
creatitis (11, 33, 49). We speculate that restoration of pancreatic
ductal fluid and HCO3 secretion could be beneficial in the early
phase of biliary pancreatitis.
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Ursodeoxycholic acid (UDCA) is a secondary, hydrophilic
bile acid, which is currently used for gallstone dissolution and
considered as first-choice therapy for various liver diseases,
such as cholelithiasis, primary biliary cirrhosis or sclerosing
cholangitis (10, 14, 36, 47). The mechanism by which UDCA
increases liver function is not completely understood. Basi-
cally, there are three concepts for the action of UDCA: 1)
stimulation of hepatobiliary secretion, 2) displacement of the
hydrophobic, toxic bile acids from the liver, and 3) direct
cytoprotection against toxic bile acids. The cytoprotective
effects of UDCA or its taurin-conjugated form, tauroursode-
oxycholic acid (TUDCA), have been widely investigated in the
liver. Studies on hepatocytes have shown that UDCA pretreat-
ment significantly reduces bile acid-induced opening of the
mitochondrial permeability transition pore (mPTP) and conse-
quently apoptosis (8, 37, 41–43, 50), indicating that stabiliza-
tion of the mitochondrial membrane, at least in part, plays an
important role in the cytoprotective action of UDCA. Because
the CDCA-induced failure in pancreatic ductal function is also
strongly associated with mitochondrial damage, we wondered
whether UDCA pretreatment is able to prevent the CDCA-
induced ductal injury. Therefore, we tested whether the toxic
effect of CDCA on pancreatic ducts can be attenuated by the
hydrophilic bile acid, UDCA.
Using in vitro and in vivo approaches, we demonstrated for
the first time that UDCA 1) completely prevented the inhibi-
tory effect of CDCA on ductal acid-base transporters, 2)
decreased the rate of CDCA-induced mitochondrial injury, 3)
and decreased the rate of CDCA-induced cell death, and 4)
reduced the severity of experimental AP induced by CDCA.
MATERIALS AND METHODS
Ethics. All experiments were conducted in compliance with the
Guide for the Care and Use of Laboratory Animals (National Acad-
emies Press, 8th ed., 2011), with the 2010/63/EU guideline and the
Hungarian 40/2013 (II.14.) government decree. The experiments were
approved by the Committee on Investigations Involving Animals at
the University of Szeged and also by independent committees assem-
bled by local authorities (XII./3773/2012.).
Solutions and chemicals. The standard Na-HEPES solution con-
tained (in mM): 130 NaCl, 5 KCl, 1 CaCl2, 1 MgCl2, 10 D-glucose,
and 10 Na-HEPES. NH4Cl-HEPES solution was supplemented with
20 mM NH4Cl, while NaCl concentration was lowered to 110 mM.
HEPES-buffered solutions were gassed with 100% O2, and their pH
was set to 7.4 with HCl. The standard HCO3/CO2-buffered solution
contained (in mM): 115 NaCl, 25 NaHCO3, 5 KCl, 1 CaCl2, 1 MgCl2,
and 10 D-glucose. NH4Cl-HCO3/CO2 solution was supplemented
with 20 mM NH4Cl, while NaCl concentration was lowered to 95
mM. HCO3/CO2-buffered solutions were gased with 95% O2-5%
CO2, and their pH was set to 7.4 with NaOH.
Chromatographically pure collagenase was purchased from Wor-
thington (Lakewood, NJ). 2,7-Bis-(2-carboxyethyl)-5-(and-6-)carboxy-
fluorescein, acetoxymethyl ester (BCECF AM), 5-oxazolecarboxylic,
2-[6-[bis(carboxymethyl) amino]-5-[2-[2-[bis(carboxymethyl)amino]-5-
methylphenoxy]-ethoxy]-2-benzofuranyl]-5-oxazolecarboxylic acetoxy-
methyl ester (fura-2 AM), calcein acetoxymethyl ester (calcein AM),
tetramethylrhodamine methyl ester (TMRM) and magnesium green ace-
toxymethyl ester (MgGreen AM) were from Life Technologies (Grand
Island, NY). Apoptotic cells were quantified by using an in situ cell death
detection kit from Roche Diagnostics (Mannheim, Germany). Bile acids
and all other chemicals were obtained from Sigma-Aldrich (Budapest,
Hungary).
Isolation and culture of the ducts. Small intrainterlobular ducts
were isolated from the pancreas of guinea pigs weighing 150–250 g.
The guinea pig was humanely killed by cervical dislocation, the
pancreas was removed and intrainterlobular ducts were isolated, as
described previously (3). The ducts were cultured overnight in a 37°C
incubator gased with 5% CO2-95% air.
Bile acid treatments. Isolated pancreatic ducts were treated with
bile acids as follows: no treatment (control group), 5-min CDCA (1
mM) treatment (CDCA group), 24-h UDCA (0.5 mM) treatment
(UDCA group), and 24 h preincubation with 0.5 mM UDCA, and then
parallel incubation for further 5 min with 1 mM CDCA
(UDCACDCA group).
Measurement of intracellular Ca2 concentration, pH, and ATP
level. Intracellular Ca2 concentration ([Ca2]i), intracellular pH
(pHi), and intracellular ATP level (ATPi) were measured by loading
the pancreatic ducts with the Ca2-sensitive fluorescent dye, fura-2 AM
(5 M, 60 min, in the presence of 0.05% pluronic F-127), the pH-
sensitive fluorescent dye, BCECF AM (2 M, 30 min), and the Mg2-
sensitive fluorescent dye, MgGreen AM (5 M, 60 min, in the presence
of 0.05% pluronic F-127), respectively. Ducts were attached to a poly-
L-lysine-coated coverslip (24 mm) forming the base of a perfusion
chamber and were mounted on the stage of an inverted fluorescence
microscope linked to an Xcellence imaging system (Olympus, Budapest,
Hungary). Ducts were then bathed with different solutions at 37°C at the
perfusion rate of 5 or 6 ml/min. Six or seven region of interests (ROIs)
were examined in each experiments, and one measurement per second
was obtained.
To determine the changes of [Ca2]i, cells were excited with 340-
and 380-nm wavelength, and the changes in [Ca2]i were calculated
from the 340/380 fluorescence ratio measured at 510 nm. To estimate
pHi, cells were excited with 490- and 440-nm wavelength, and the
490/440 fluorescence emission ratio was measured at 535 nm. The
calibration of the fluorescent emission ratio to pHi was performed
with the high-K-nigericin technique, as previously described (19,
56). Changes in [ATP]i was determined by exciting the cells at a
wavelength of 490 nm, with emitted light monitored at 535 nm.
Fluorescence signals were normalized to initial fluorescence intensity
(F/F0) and expressed as relative fluorescence.
Measurement of acid/base transporter activity. To estimate the
activity of Na/H exchanger (NHE), the Na/HCO3 cotransporter
(NBC), and Cl/HCO3 exchanger (CBE), the NH4Cl prepulse tech-
nique was used. Briefly, exposure of pancreatic ducts to 20 mM
NH4Cl for 3 min induced an immediate rise in pHi due to the rapid
entry of lipophilic, basic NH3 into the cells. After the removal of
NH4Cl, pHi rapidly decreased. This acidification is caused by the
dissociation of intracellular NH4 to H and NH3, followed by the
diffusion of NH3 out of the cell. In standard HEPES-buffered solution,
the initial rate of pHi (pH/t) recovery from the acid load (over the
first 60 s) reflects the activities of NHEs, whereas in HCO3/CO2-
buffered solutions represents the activities of both NHEs and NBC
(18, 20). To estimate CBE activity, the initial rate of pHi recovery
from alkalosis in HCO3/CO2-buffered solutions was analyzed. Pre-
vious data have indicated that under these conditions, the recovery
over the first 30 s reflects the activity of CBE (18, 20).
To evaluate transmembrane base flux [J(B)], the following equa-
tion was used: J(B)  pH/t  total, where pH/t was
calculated by linear regression analysis; the total buffering capac-
ity (total) was estimated by the Henderson-Hasselbach equation
using the following formula: total  i  HCO3  i  2.3 
[HCO3]i. We denote base influx as J(B) and base efflux (secretion)
as J(B).
Measurement of mitochondrial membrane potential. Mitochondrial
membrane potential (	m) was measured using the lipophilic, mito-
chondria-selective fluorescence dye, TMRM. Accumulation of
TMRM in the mitochondria depends on the 	m. Pancreatic ducts
were preincubated with TMRM (1 M) for 30 min at 37°C and were
transferred to a poly-L-lysine-coated coverslip (24 mm) forming the
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base of a perfusion chamber. Ducts were then perfused continuously
with solutions at 37°C at a rate of 2–2.5 ml/min. The perfusion
solutions were complemented with 100 nM TMRM to avoid dye
leakage. Changes in 	m were monitored using a FluoView 10i-W
confocal microscope (Olympus, Budapest, Hungary). Five to ten ROIs
(mitochondria) of 5–10 cells were excited with light at 543 nm, and
the emitted light was captured between 560 and 650 nm. We have
used the dequench method for the estimation of 	m. At the applied
concentration of TMRM, depolarization of the mitochondria causes
release of the dye and its dequenching in the cytosol. Thus, increase
in fluorescence intensity reflects a decrease in 	m. Fluorescence
signals were normalized to initial fluorescence intensity (F/F0) and
were expressed as relative fluorescence.
Measurement of mitochondrial permeability transition pore
opening. To measure mitochondrial inner membrane permeabilization
and/or the opening of the mitochondrial permeability transition pore
(mPTP), we used the calcein-cobalt dequenching technique. Calcein
AM is a lipid-soluble fluorescent dye that diffuses into all subcellular
components, including mitochondria. Co2 is a quencher of calcein,
which can enter to the cytoplasm but cannot pass through the mito-
chondrial membrane. Upon transient opening of mPTP, Co2 diffuses
into the mitochondria and quenches the mitochondrial calcein fluo-
rescence, which results in a decrease of fluorescence intensity. Pan-
creatic ducts were loaded with calcein-AM (1 M) for 30 min, and
then with CoCl2 (1 mM) for a further 10 min. Ducts were then washed
at 37°C at the perfusion rate of 5–6 ml/min and imaged using an
Olympus IX71 fluorescence microscope (Olympus, Budapest, Hun-
gary). Five or six ROIs were excited with light at 495 nm, and the
emitted light was captured at 515 nm. Fluorescence signals were
normalized to initial fluorescence intensity (F/F0) and expressed as
relative fluorescence.
TUNEL cell death assay. For detection of cell death, we used the
terminal deoxyribonucleotidyl transferase-mediated dUTP-digoxige-
nin nick-end labeling (TUNEL) assay (Roche Diagnostics). Intrainter-
lobular pancreatic ducts were treated with bile acids, as previously
described. Control and bile acid-treated isolated duct segments were
fixed with 4% paraformaldehyde overnight and then cryosectioning
and staining of the samples were performed, according to the manu-
facturer’s protocol. The CDCA-treated groups were incubated for 3 h
in culture media before fixation. Pictures were taken with the use of
a Zeiss AxioImager fluorescent light microscope (Carl Zeiss Micro-
Imaging, Thornwood, NY) fitted with a PixeLINK CCD camera
(PixeLINK, Ottawa, ON, Canada).
Transmission electron microscopy. For electron microscopic stud-
ies, ducts were fixed in 2.5% glutaraldehyde immediately after isola-
tion. Samples were then postfixed in 1% osmium tetroxide, dehy-
drated in a series of graded ethanols, and subsequently embedded in
epoxy resin. Ultrathin sections were contrasted with uranyl acetate
and lead citrate. Tissue sections were analyzed under a transmission
electron microscope (CM10; Philips, Eindhoven, The Netherlands).
Induction of acute pancreatitis. Male Sprague-Dawley rats weigh-
ing 200–250 g were used for all experiments. Rats were kept at
constant room temperature of 24°C with a 12:12-h light and dark
cycle and were allowed free access to tap water and standard labora-
tory chow (Biofarm, Zagyvaszaántó, Hungary). Animal were fasted
12 h before the surgical procedure. All experiments were approved by
the Institutional Animal Care and Use Committee of the University of
Szeged (I-74-3/2012 MÁB) and also by an independent committee
assembled by national authorities (XII./3773/2012.). Rats were ran-
domly allocated into four groups (n  6) as follows: 1) control
(intraductal administration of physiological saline), 2) UDCA (rats
were treated with oral UDCA without induction of pancreatitis), 3)
CDCA (pancreatitis was induced by intraductal administration of
CDCA), and 4) UDCACDCA (rats were treated with oral UDCA
and pancreatitis was induced with intraductal administration of
CDCA). Ursodeoxycholic acid (Ursofalk) was purchased from Dr.
Falk Pharma. UDCA was dissolved in 2 ml of tap water and was
administered orally (gavage) 250 mg/kg body wt daily for 2 wk. The
pretreatment period was chosen on the basis of studies investigating
cholestatic diseases (26, 57). Control animals were only treated with
the same amount of tap water. The last UDCA treatment was per-
formed one day before the AP induction.
Rats were anesthetized with intraperitoneal injection of a cocktail
containing of 50 mg/kg ketamine and 10 mg/kg xylazine. After the
anesthesia, rats were shaved, and the abdominal cavity was opened
with median laparotomy. The common bile duct was temporarily
occluded with a vessel clip. The duodenum was punctured with a
0.4-mm diameter needle connected to polyethylene tubing, then it was
placed into the pancreatic duct and 1 ml/kg 1% sodium-CDCA
(dissolved in physiologic saline) was administered via retrograde
ductal infusion with 1 ml/min speed with an infusion pump (TSE
System, Bad Homburg, Germany). Control animals received intraduc-
tal physiological saline instead of bile acid. After bile acid or physi-
ological saline infusion, the vessel clip and the polyethylene tube were
removed, and the abdominal wall and skin were closed. Rats were
killed 24 h after the surgical procedure.
Histologic examination and laboratory parameter measurements.
Terminal anesthesia was performed with 50 mg/kg pentobarbital
sodium. The abdominal and thoracic cavities were opened with a
median laparotomy and thoracotomy and blood was collected with
cardiac puncture. The pancreas was removed immediately after the
blood collection, and it was trimmed from fat and lymphatic tissues on
ice. Pancreata were dissected and only parts of the head and body
were used for histological analysis and for laboratorial measurements.
Sections from the pancreatic tail did not show any signs of necrosis or
inflammation; therefore, it was not used later. The pancreatic head and
body were longitudinally dissected, and one part of pancreas was put
into 6% neutral formaldehyde solution, while the other part was
immediately frozen in liquid nitrogen. These parts of pancreata were
stored at80°C until further use. The collected blood was centrifuged
at 4°C with 2500 RCF for 15 min. Sera were eventually stored at
20°C until use.
Serum amylase activity was measured with a commercial colori-
metric kit (Diagnostikum, Budapest, Hungary) with a FLUOstar
OPTIMA (BMG Labtech, IronMaas Consulting, Budapest Hungary)
microplate reader at 405 nm. Wet pancreatic tissues were measured,
and they were dried for 24 h at 100°C. The dry weight-wet weight
ratio was calculated. Pancreatic samples were prepared for hematox-
ylin-and-eosin staining. Pancreatic histological samples were scanned.
Necrotic areas were detected and analyzed with Image J (National
Institutes of Health, Bethesda, MD) software. Necrotic areas were
compared with the total analyzed pancreatic area.
Statistical analysis. Data are expressed as means 
 SE. Significant
difference between groups was determined by ANOVA. Statistical
analysis of the immunohistochemical data was performed using the
Mann-Whitney U-test. Probability values of P  0.05 were accepted
as being significant.
In vivo experiments were evaluated by using ANOVA followed by
Bonferroni or Dunnett’s multiple-comparison post hoc test.
RESULTS
Effect of UDCA and CDCA on intracellular pH. Previous
studies have shown that bile acids induce intracellular acidifi-
cation in several cell types (2, 16, 32, 59). Therefore, first, we
investigated the effect of CDCA and UDCA on basal intracel-
lular pH (pHi) of pancreatic ducts. Administration of CDCA
induced a dose-dependent intracellular acidification in HEPES-
buffered solution (Fig. 1A). The effect of CDCA on pHi was
reversible, following the removal of bile acid from the external
solution, the pHi completely returned to the basal level. UDCA
also induced a dose-dependent decrease in pHi; however, the
effect of UDCA was much smaller compared with CDCA (Fig.
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1B). We repeated these experiments in HCO3/CO2-buffered
solution, where the two bile acids induced similar degrees of
pHi decrease (Fig. 1, C and D). Summary of the changes of pHi
is shown in Fig. 1, E and F.
UDCA pretreatment prevents the inhibitory effect of CDCA
on acid-base transporters. To investigate the acid-base trans-
porters of pancreatic ducts, we used the ammonium prepulse
technique. In the absence of HCO3, the initial recovery from
the acid phase is due to the activity of the NHE (Fig. 2A). In
the presence of HCO3, the recovery from alkalosis reflects
the activity of the Cl/HCO3 exchanger (CBE), whereas the
recovery from acidosis results from the activity of both NHE
and Na/HCO3 cotransporter (NBC) (Fig. 2B). Two NH4Cl
pulses were applied: the first was the control, and the second
was the test. To estimate the effect of bile acids on the
activity of acid-base transporters CDCA (1 mM) and UDCA
(0.1, 0.25, 0.5, and 1 mM) were administered 3 min before
the pulse, during the pulse, and 5 min after the pulse. Acute
administration of UDCA did not affect the rate of recovery
from the acid or alkali load either in HEPES-buffered nor in
HCO3/CO2-buffered solutions (data not shown). In con-
trast, 1 mM CDCA strongly inhibited the activity of the
acid-base transporters. (Fig. 2, A and B) Next, we tested
whether UDCA administration can influence the inhibitory
effect of CDCA. When UDCA and CDCA were added
simultaneously, UDCA was unable to prevent the inhibitory
effect of CDCA on the ion transporters in all of the inves-
tigated concentration (data not shown). Several studies have
shown that prolonged preincubation of the cells with UDCA
is needed to exert its protective effect (21, 22, 48, 50).
Therefore, in the next step, we pretreated the ducts with
UDCA for various time periods (5 h and 24 h), and the effect
of CDCA on the ion transporters was examined. A 5-h
preincubation of the ducts with UDCA (0.1, 0.25, 0.5, and 1
mM) did not affect the response to CDCA. However, 24-h
pretreatment with UDCA significantly decreased the toxic
effect of CDCA both in HEPES (Fig. 2A) and in HCO3/
CO2-buffered (Fig. 2B) solutions. The lowest concentration
of UDCA, which had a protective effect was 0.5 mM (Fig.
2, A and B), whereas at higher concentrations (1 mM), the
protective effect of UDCA was significantly decreased.
Therefore, we decided to use 0.5 mM UDCA in the subse-
quent experiments. Summary data of the base fluxes [

J(B/min)] are shown on Fig. 2, C–E. As shown, pretreat-
ment of the ducts with 0.5 mM UDCA prevented the
inhibitory effect of CDCA on NHE (Fig. 2C), CBE (Fig.
2D), and NBC (Fig. 2E).
UDCA pretreatment had no effect on the CDCA-induced
calcium signaling. Several studies have indicated that bile-
induced toxic calcium signaling is an initial step in the devel-
opment of AP (25, 31, 38, 58). We have previously shown that
high concentration of CDCA induces (Ca2) elevation in
ductal cells (59). So, in the next step, we have examined
whether UDCA pretreatment has any effect on the CDCA-
induced Ca2 signaling. Administration of 0.5 mM UDCA
alone had no significant effect on [Ca2]i (data not shown). In
contrast, 1 mM CDCA induced high and partially reversible
Ca2 signaling in pancreatic ducts. (Fig. 3A) Preincubation of
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Fig. 1. Effect of bile acids on the intracellular pH (pHi) of isolated guinea pig pancreatic ducts. Pancreatic ducts were exposed to 0.1, 0.25, 0.5, and 1 mM
chenodeoxycholic acid (CDCA; A and C) or ursodeoxycholic acid (UDCA; B and D) in HEPES- (A and B) and in HCO3/CO2-buffered (C and D) solutions for
5 min. After the removal of bile acids, the intracellular pH (pHi) spontaneously recovered. Bar charts show summary data for the maximal pHi change (pHmax)
induced by bile acids in HEPES- (E) and in HCO3/CO2-buffered (F) solutions. The starting pHi for the measurement of pH was the pHi immediately before
exposure to bile acids. Data are presented as means 
 SE; n  32–34 regions of interest from 4 or 5 ducts.
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the ducts with 0.5 mM UDCA for 24 h did not affect the
CDCA-induced increase in [Ca2]i, (Fig. 3, A and B), indicat-
ing that the protective effect of UDCA is unlikely to be caused
by the prevention of the elevated [Ca2]i.
UDCA pretreatment decreased the rate of CDCA-induced
mitochondrial injury. Increasing number of studies indicate the
importance of mitochondrial injury in cell death (27, 28). We
have previously shown that beside the elevated Ca2 signaling,
CDCA strongly damages mitochondria and causes ATPi de-
pletion in pancreatic ducts, which may contribute to the inhib-
itory effect of CDCA on ion transporters due to bioenergetic
failure (29). Therefore, in the next series of experiments we
performed both functional and morphological studies to char-
acterize the effect of UDCA pretreatment on CDCA-induced
mitochondrial injury.
The level of ATPi is a good indicator of mitochondrial
function; therefore, in the first step, we measured changes in
ATPi in cells exposed to CDCA with or without UDCA
pretreatment. As shown on Fig. 3C, administration of 1 mM
CDCA caused a huge and irreversible ATPi loss in PDECs
(Fig. 3C). In contrast, 24 h preincubation of the cells with 0.5
mM UDCA reduced the rate of CDCA-induced ATPi decrease
by 57.6
 3.6% (Fig. 3, C and D). UDCA administration alone
did not affect ATPi.
To further analyze the protective effect of UDCA on ductal
mitochondria, we also investigated 	m and mPTP upon
administration of bile acids. Ducts were incubated with 1 M
TMRM to investigate the changes in 	m (see MATERIALS AND
METHODS). After the stabilization of the mitochondrial fluores-
cence, 1 mM CDCA was applied and the fluorescence signal
was monitored. As shown in Fig. 3E, the administration of
CDCA resulted in a huge increase in TMRM fluorescence
intensity, indicating that this bile acid induced marked
mitochondrial depolarization. Preincubation of the ducts
Fig. 3. Effect of bile acids on intracellular Ca2 concentration ([Ca2]i), ATP level (ATPi), mitochondrial membrane potential (	m), and mitochondrial
permeability transition pore (mPTP) opening of pancreatic ducts. Representative experimental traces showing the effect of 1 mM CDCA on [Ca2]i (A), ATPi
(C), 	m (E), and mPTP opening (G) in nonpretreated and 24-h UDCA pretreated pancreatic ducts. A: acute administration of CDCA caused Ca2 signalization
in pancreatic ductal cells, which was not affected by UDCA pretreatment. C: decrease in ATPi is shown by an increase in fluorescence intensity. Twenty-four
hours of UDCA pretreatment markedly decreased the CDCA-induced ATP depletion. E: decrease in 	m is shown by an increase in tetramethylrhodamine
methyl ester (TMRM) fluorescence intensity. Administration of 1 mM CDCA caused rapid depolarization of the mitochondrial membrane, which was decreased
by UDCA pretreatment. G: mPTP opening is shown by a decrease in fluorescence intensity. CDCA-induced a marked mPTP opening that resulted in significant
influx of Co2 into the mitochondria causing decrease in calcein fluorescence. Twenty-four hours of UDCA pretreatment reduced CDCA-induced mPTP opening
resulting in milder decrease in calcein fluorescence. Summary data for the maximal fluorescence intensity changes are shown in B, D, F, and H. Data are presented
as means 
 SE. *P  0.05 vs. 1 mM CDCA; n  35–40 regions of interest from 6 or 7 ducts.
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with 0.5 mM UDCA reduced the CDCA-induced depolar-
ization by 69.4 
 4.6% (Fig. 3, E and F).
Because ATP depletion and mitochondrial depolarization
are caused by mPTP induction, next we investigated the effect
of CDCA on the opening of mPTP using the calcein-cobalt
technique. Treatment of the calcein-loaded pancreatic ducts
with 1 mM CDCA decreased the fluorescence excitation of
calcein, 1 min after the addition of the bile acid. (Fig. 3G)
Similarly to the 	m experiments, 24-h pretreatment of the
ducts with 0.5 mM UDCA had a protective role in mito-
chondria and decreased the CDCA-induced mPTP opening
by 72.1 
 4%. (Fig. 3, G and H) Administration of UDCA
alone did not affect mPTP.
We also examined the morphology of the ductal mitochon-
dria using electron microscopy (Fig. 4, A–D). The mean
number of mitochondria in the section of the control, the
CDCA, the UDCA, and the CDCAUDCA groups was nearly
the same. No morphological alterations were observed in the
control and UDCA-treated groups. (Fig. 4, A and B) In con-
trast, incubation of the ducts with 1 mM CDCA for 5 min
resulted in mitochondrial swelling and the loss of the mito-
chondrial inner membrane (Fig. 4C). This swelling could be
prevented by UDCA pretreatment. Moreover, the integrity of
the mitochondria was also maintained in the CDCAUDCA-
treated ducts compared with the ducts only treated with CDCA
(Fig. 4D).
UDCA pretreatment prevented the CDCA-induced cell
death. In the next step, we tested whether the toxic effect of
CDCA on the mitochondria is associated with cell death. Ducts
were treated with 1 mM CDCA for 5 min, then they were
incubated in culture media for further 3 h to leave time for
development of cell death. Cell death was assessed by TUNEL
staining (Fig. 5, A and B). This method is based on the labeling
of the 3=-OH ends of the fragmented DNA, which are gener-
ated during cell death. Incubation of the pancreatic ducts with
CDCA resulted in a significant increase in cell death compared
with control, nontreated ducts. (Fig. 5, A and B) Although, both
apoptosis and necrosis can be characterized by DNA fragmen-
tation (17), the presence of intact cell organelles, cellular
shrinkage, and the lack of cellular content release indicate that
CDCA rather induces apoptotic cell death than necrosis. Twen-
ty-four hour preincubation with UDCA (0.5 mM) alone caused
only a small degree of DNA fragmentation in the ductal cells,
A B
C D
Fig. 4. Effect of bile acids on the morphology
of pancreatic ductal mitochondria. Represen-
tative electron micrograph images of pancre-
atic ductal mitochondria show normal mito-
chondria with intact inner membranes in the
control (A) and 24 h UDCA (0.5 mM) pre-
treated ducts (B). Treatment with 1 mM
CDCA caused mitochondrial swelling after 5
min (C), which was completely prevented by
24 h UDCA (0.5 mM) pretreatment (D).
Arrows show mitochondria.
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Fig. 5. Effect of UDCA pretreatment on
CDCA-induced cell death on pancreatic duc-
tal epithelial cells (PDECs). A: representa-
tive pictures of TUNEL-positive and eosin-
stained pancreatic duct segments show that
incubation of the pancreatic ducts with 1
mM CDCA (left bottom), increased the rate
of dead cells compared with control (top,
left) nontreated ducts. Five-minute adminis-
tration of UDCA (0.5 mM) alone, had no
significant effect on the cells (top, right),
whereas 24-h pretreatment of the ducts with
0.5 mM UDCA (bottom, right) decreased the
rate of dead cells in the CDCA-treated
group. B: bar chart shows the percentage of
total cell counts that are TUNEL positive.
Data are presented as means 
 SE. *P 
0.05 vs. Control, #P  0.05 vs. 1 mM
CDCA, n  3 or 4.
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but significantly reduced the CDCA-induced apoptotic cell
death by 63.3 
 5.7%. (Fig. 5, A and B)
Oral administration of UDCA attenuates CDCA-induced
pancreatitis in vivo. To investigate the protective effect of
UDCA under in vivo conditions, we utilized a CDCA-induced
pancreatitis model (53, 54). We used rats as the model animals
because we were unable to administer CDCA intraductally in
guinea pigs due to the anatomical topography of the main duct.
Serum amylase activities were significantly elevated after
retrograde infusion of CDCA (CDCA group: 983 
 100 U/l)
compared with intraductally administered physiological saline
(control group: 396
 50 U/l). Pretreatment of UDCA for 2 wk
did not influence the serum amylase activities (UDCA group:
424.7 
 20) in control animals; however, it was significantly
decreased (582 
 50 U/l) in the UDCACDCA group vs. the
CDCA group (Fig. 6A).
Pancreatic water content was significantly elevated after
retrograde infusion of CDCA (80 
 1%) compared with
intraductally administered physiological saline (60 
 1%). A
2-wk pretreatment with UDCA showed no influence on the
pancreatic water content (61 
 2%) in the UDCA group.
However, in the UDCACDCA group, it was significantly
decreased (65 
 2%) vs. the CDCA group (Fig. 6B).
Pancreatic damage was characterized by determining the
extent of tissue necrosis (Fig. 6, C and D). Intraductal infusion
of physiological saline with or without UDCA pretreatment did
not cause any acinar cell necrosis. However, retrograde infu-
sion of CDCA caused markedly elevated (14
 2%) acinar cell
damage, which was significantly ameliorated (6 
 2%) in the
UDCACDCA group (Fig. 6C).
DISCUSSION
Bile reflux into the pancreas may lead to pancreatic injury
and as a result can induce AP (34). Therefore, a better under-
standing of the mechanisms underlying bile-induced pancreatic
injury and its prevention may provide novel therapeutic tools
for the treatment of AP. In the present study, we have shown
for the first time that the hydrophilic bile acid UDCA is able to
attenuate the toxic effect of CDCA on pancreatic ducts by
preventing CDCA-induced mitochondrial injury.
We used isolated intrainterlobular pancreatic ducts, which is
a reliable in vitro model for investigating pancreatic ductal
damage. The CDCA concentration used in this study was
previously shown to induce intracellular Ca2 signaling, mi-
tochondrial injury, and inhibition of the acid-base transporters
(29, 59), whereas the concentrations of UDCA were chosen on
the basis of the literature data (42, 43). Examinations were
performed using 0.5 mM UDCA, since the protective effect of
UDCA was not increased by using higher concentrations (1
mM), whereas lower concentrations of this bile acid (0.1 and
0.25 mM) had no detectable protective effect. This concentra-
tion of UDCA is one magnitude higher than the physiological
concentration of bile acid in the blood (9) and several orders of
magnitude lower than the concentration of bile acids in the gall
bladder or duodenum (10–100 mM). The optimal preincuba-
tion time of pancreatic ducts with UDCA was found to be 24
h, indicating that the development of protective action is a
complex mechanism, which probably includes changes at the
transcriptional level that modulate various signaling and apo-
ptotic pathways (42, 43, 51, 52).
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Fig. 6. Effect of UDCA pretreatment on CDCA-induced pancreatitis in rats. Serum amylase activity (U/l) (A), pancreatic edema (B), and cell necrosis (C) were
significantly increased by intraductal administration of CDCA. However, 2 wk of UDCA pretreatment ameliorated each of these severity parameters. D:
representative histological images of control, UDCA-pretreated, CDCA-induced acute pancreatitis, and UDCA-pretreated, CDCA-induced acute pancreatitis
animals. Control rats were given physiological saline instead of CDCA. PS, physiological saline; P.O., per os; I.D., intraductal. Data are presented as means 
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In the present study, we demonstrated that 24-h pretreatment
of pancreatic ducts with 0.5 mM UDCA significantly reduced
the inhibitory effect of CDCA on the acid/base transporters.
Studies on pancreatic acinar cells have indicated that the toxic
effect of hydrophobic bile acids is mediated by a sustained
Ca2 signaling (15, 61). We have previously shown that a high
concentration of CDCA induces a huge and long-lasting ele-
vation of [Ca2]i in pancreatic ducts.(59) Therefore, we tested
whether the protective effect of UDCA on the acid/base trans-
porters is due to the prevention of CDCA-induced calcium
signaling. When pancreatic ducts were exposed to UDCA for
24 h and CDCA was then added, the extent of calcium
elevation did not change, indicating that the protective effect of
UDCA is unlikely to be caused by the reduction of Ca2
signaling. This finding is in accordance with our previous
observation on pancreatic ducts, where preincubation of the
cells with a specific calcium chelator, BAPTA AM was unable
to prevent the inhibitory effect of CDCA on acid-base trans-
porters (59).
An increasing number of studies support the concept that
mitochondrial damage plays a central role in the bile-induced
cellular injury and that UDCA pretreatment is able to attenuate
the toxic effect of hydrophobic bile acids on mitochondria.(8,
41–43) Therefore, in the next step, we investigated the protec-
tive effect of UDCA on the function and morphology of
pancreatic ductal mitochondria. Administration of CDCA
alone induced mPTP opening in the ductal cells. This is an
early event in cell death that leads to mitochondrial swelling
due to an increase in the mitochondrial inner membrane per-
meability. mPTP is also characterized by the loss of membrane
potential, which leads to mitochondrial dysfunction and con-
sequently inhibition of ATP synthesis. We did not investigate
the exact mechanism by which CDCA induces mPTP opening.
Studies on rat hepatocytes demonstrated that in the presence of
the specific mPTP inhibitor, cyclosporine A, the effect of
CDCA was completely ameliorated, indicating that CDCA
selectively acts on mPTP (45). It has been also demonstrated
that CDCA induces mPTP due to increased membrane fluidity
and cytochrome-c release in calcium-loaded hepatic mitochon-
dria (44). In contrast to the effects of CDCA, UDCA alone
caused no significant changes in mitochondrial function. How-
ever, in combination with CDCA, UDCA was able to prevent
the CDCA-induced mPTP, mitochondrial membrane perturba-
tion, and the consequently formed decrease in membrane
potential. Moreover, UDCA prevented the CDCA-induced
ATPi loss, which provides further evidence that UDCA pre-
treatment is beneficial to avoid mitochondrial injury. This
conclusion was confirmed by electron microscopic studies,
which showed normal appearance of mitochondria in the
UDCACDCA group compared with the CDCA group, where
mitochondrial swelling and disruption of the inner mitochon-
drial membrane were observed. The mechanism underlying the
mitochondrial protective effect of UDCA is not clear. One of
the main inducers of mPTP is Ca2 overload and oxidative
stress. Although we have shown that UDCA pretreatment had
no effect on the extent of CDCA-induced Ca2 elevation, we
did not investigate the effect of UDCA on the total Ca2 load.
It is possible that the protective effect of UDCA is due to the
reduction of Ca2 overload or by the inhibition of reactive
oxygen species (ROS) production; however, further studies are
needed to confirm these hypotheses.
Mitochondrial dysfunction is often associated with cell death
either by the reduction of ATPi levels or by irreversible
alterations in the mitochondrial membrane permeability, which
induces the release of apoptotic signaling molecules from the
mitochondria. Since mitochondria play a central role in cell
survival, we wanted to determine whether the CDCA-induced
mitochondrial injury would result in cell death and to examine
the possible protective role of UDCA in this process. Admin-
istration of CDCA induced marked DNA fragmentation in
intact pancreatic ducts. We speculate that impairment of mito-
chondrial function plays a central role in this mechanism, but
other signaling pathways may be involved. The apoptotic
effect of CDCA and other hydrophobic bile acids have been
examined in more detail in hepatocytes. ROS generation,
mPTP induction, cytochrome-c release and activation of down-
stream caspases have been shown to be associated with apo-
ptosis (65, 66). It has been also demonstrated that the glycine-
conjugated form of CDCA, directly stimulate Fas-dependent
cell death due to the activation of the Fas receptor, which is
independent from the mitochondrial pathway (13). Twenty-
four hour pretreatment with UDCA effectively reduced the
CDCA-induced apoptosis as indicated by significantly de-
creased DNA fragmentation, which further confirms the cyto-
protective effect of UDCA. The exact mechanism by which
UDCA exerts its protective effect was not investigated by our
group; however, our results and previous studies on hepato-
cytes strongly indicate that mPTP inhibition by UDCA is one
of the key mechanisms in the reduction of CDCA-induced cell
death in PDECs.
To extend our study, we also tested the protective effect of
UDCA in vivo. There is no accepted pancreatitis model in
guinea pigs; therefore, we induced AP in rats by intraductal
injection of low concentration of CDCA (53, 54). Under these
experimental conditions, CDCA induced acinar cell damage
and also increased serum amylase activity. Previous studies on
UDCA
CDCA
Mitochondrial membrane
depolarization and MPTP 
opening
Energetic breakdown
Cell death
Loss of ATP
Fig. 7. Proposed model for the protective effect of UDCA. CDCA induces
mitochondrial damage by decreasing mitochondrial membrane potential and
opening of mitochondrial permeability transition pore (MPTP). UDCA is able
to prevent the toxic effect of CDCA by the stabilization of the mitochondrial
membrane. ¡, induction; |——, inhibition.
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isolated rat and mouse acini demonstrated that the hydrophobic
bile acid, TLC-S induces mitochondrial injury, pathological
Ca2 signaling, and the generation of ROS (7, 61–63). We
speculate that similar intracellular mechanisms may also have
arisen in response to CDCA. The CDCA-induced acinar cell
injury, hyperamylasemia, and pancreatic edema were markedly
reduced in the UDCA-treated group. The protective effect of
UDCA can be attributed to its ability to reduce mitochondrial
injury both in acinar and ductal cells. Several attempts have
been made to investigate the effect of UDCA on isolated
pancreatic acinar cells. Using rat and mouse acinar cells, we
found that isolated acinar cells are more sensitive to long-term
bile acid treatment than ductal cells, which made the investi-
gation of the protective effect of UDCA very difficult. Cell
viability experiments showed that even at low concentrations,
bile acids decreased the viability of isolated acinar cells, and in
contrast to ductal cells, UDCA pretreatment had no protective
effect on acinar cells under our experimental conditions (data
not shown).
Lastly, our results may have important clinical implication
in patients with gallstone obstruction, where oral administra-
tion of UDCA, or its metabolically stable form, may reduce the
risk of pancreatitis development. The beneficial effect of
UDCA treatment has been demonstrated in idiopathic recurrent
pancreatitis, in which long-term UDCA treatment reduced the
rate of recurrence by prevention of the formation of gallstones
(46, 55, 60). The effect of orally administered UDCA is highly
dependent on its metabolism. In rats, most of the UDCA is
metabolized to TUDCA (40), which also has a cytoprotective
effect as demonstrated in the liver (4, 5, 37, 50). In humans,
one of the major metabolites of UDCA is isoursodeoxycholic
acid (or isoUDCA) (6), which is the 3-hydroxy epimer of
UDCA and has been shown to be more effective than UDCA
(30). In the current study, we have not investigated the serum
concentration of UDCA after oral administration. Notably,
since UDCA was administered in an excess dose, we believe
that sufficiently high concentration of UDCA (or TUDCA) was
present in the serum to exert its protective effect.
Understanding the early injury mechanisms induced by
hydrophobic bile acids is extremely important to find a thera-
peutic target to reduce pancreatic injury. In this study, we
confirm and extend our previous observations that mitochon-
dria is a key target in the CDCA-induced cellular injury in
PDECs. The hydrophilic bile acid UDCA inhibits CDCA-
induced apoptosis probably by the stabilization of mitochon-
drial membrane via blockade of membrane depolarization and
mPTP and also by prevention of mitochondrial swelling (Fig.
7). Several studies have focused on the inhibition of cellular
injury during AP to stop or delay the progression of the
disease. UDCA may represent a novel option against the
bile-induced ductal injury; however, issues for the therapeutic
application of this bile acid in AP need further investigation.
GRANTS
This study was supported by the Hungarian National Development Agency
(Grants TÁMOP- 4.2.2.A-11/1/KONV-2012-0035, TÁMOP-4.2.2-A-11/1/
KONV-2012-0052 TÁMOP-4.2.2.A-11/1/KONV-2012-0073, TÁMOP-4.2.2./
B-10/1–2010-0012, and TÁMOP 4.2.4.A/2–11-1-2012-0001 of the National
Excellence Program), the Hungarian Scientific Research Fund (K109756 to V.
Venglovecz), and the Hungarian Academy of Sciences-University of Szeged
(MTA-SZTE) Momentum Grant (LP2014-10/2014).
DISCLOSURES
No conflicts of interest, financial or otherwise, are declared by the authors.
AUTHOR CONTRIBUTIONS
M.K., B.K., Z.B., and J.M. performed experiments; M.K. analyzed data;
P.H., Z.R.J., Z.R., L.T., and V.V. interpreted results of experiments; V.V.
conception and design of research; V.V. drafted manuscript; V.V. approved
final version of manuscript.
REFERENCES
1. Acosta JM, Ledesma CL. Gallstone migration as a cause of acute
pancreatitis. N Engl J Med 290: 484–487, 1974.
2. Alvaro D, Mennone A, Boyer JL. Effect of ursodeoxycholic acid on
intracellular pH regulation in isolated rat bile duct epithelial cells. Am J
Physiol Gastrointest Liver Physiol 265: G783–G791, 1993.
3. Argent BE, Arkle S, Cullen MJ, Green R. Morphological, biochemical
and secretory studies on rat pancreatic ducts maintained in tissue culture.
Q J Exp Physiol 71: 633–648, 1986.
4. Benz C, Angermuller S, Otto G, Sauer P, Stremmel W, Stiehl A. Effect
of tauroursodeoxycholic acid on bile acid-induced apoptosis in primary
human hepatocytes. Eur J Clin Invest 30: 203–209, 2000.
5. Benz C, Angermuller S, Tox U, Kloters-Plachky P, Riedel HD, Sauer
P, Stremmel W, Stiehl A. Effect of tauroursodeoxycholic acid on bile-
acid-induced apoptosis and cytolysis in rat hepatocytes. J Hepatol 28:
99–106, 1998.
6. Beuers U, Fischer S, Spengler U, Paumgartner G. Formation of
iso-ursodeoxycholic acid during administration of ursodeoxycholic acid in
man. J Hepatol 13: 97–103, 1991.
7. Booth DM, Murphy JA, Mukherjee R, Awais M, Neoptolemos JP,
Gerasimenko OV, Tepikin AV, Petersen OH, Sutton R, Criddle DN.
Reactive oxygen species induced by bile acid induce apoptosis and protect
against necrosis in pancreatic acinar cells. Gastroenterology 140: 2116–
2125, 2011.
8. Botla R, Spivey JR, Aguilar H, Bronk SF, Gores GJ. Ursodeoxycholate
(UDCA) inhibits the mitochondrial membrane permeability transition
induced by glycochenodeoxycholate: a mechanism of UDCA cytoprotec-
tion. J Pharmacol Exp Ther 272: 930–938, 1995.
9. Boyer JL. New concepts of mechanisms of hepatocyte bile formation.
Physiol Rev 60: 303–326, 1980.
10. de Caestecker JS, Jazrawi RP, Petroni ML, Northfield TC. Ursode-
oxycholic acid in chronic liver disease. Gut 32: 1061–1065, 1991.
11. Durie PR. Pancreatitis and mutations of the cystic fibrosis gene. N Engl
J Med 339: 687–688, 1998.
12. Farmer RC, Tweedie J, Maslin S, Reber HA, Adler G, Kern H. Effects
of bile salts on permeability and morphology of main pancreatic duct in
cats. Dig Dis Sci 29: 740–751, 1984.
13. Faubion WA, Guicciardi ME, Miyoshi H, Bronk SF, Roberts PJ,
Svingen PA, Kaufmann SH, Gores GJ. Toxic bile salts induce rodent
hepatocyte apoptosis via direct activation of Fas. J Clin Invest 103:
137–145, 1999.
14. Festi D, Montagnani M, Azzaroli F, Lodato F, Mazzella G, Roda A, Di
Biase AR, Roda E, Simoni P, Colecchia A. Clinical efficacy and
effectiveness of ursodeoxycholic acid in cholestatic liver diseases. Curr
Clin Pharmacol 2: 155–177, 2007.
15. Gerasimenko JV, Flowerdew SE, Voronina SG, Sukhomlin TK,
Tepikin AV, Petersen OH, Gerasimenko OV. Bile acids induce Ca2
release from both the endoplasmic reticulum and acidic intracellular
calcium stores through activation of inositol trisphosphate receptors and
ryanodine receptors. J Biol Chem 281: 40, 154–40, 163, 2006.
16. Goldman A, Shahidullah M, Goldman D, Khailova L, Watts G,
Delamere N, Dvorak K. A novel mechanism of acid and bile acid-
induced DNA damage involving Na/H exchanger: implication for
Barrett’s oesophagus. Gut 59: 1606–1616, 2010.
17. Grasl-Kraupp B, Ruttkay-Nedecky B, Koudelka H, Bukowska K,
Bursch W, Schulte-Hermann R. In situ detection of fragmented DNA
(TUNEL assay) fails to discriminate among apoptosis, necrosis, and
autolytic cell death: a cautionary note. Hepatology 21: 1465–1468, 1995.
18. Hegyi P, Gray MA, Argent BE. Substance P inhibits bicarbonate secre-
tion from guinea pig pancreatic ducts by modulating an anion exchanger.
Am J Physiol Cell Physiol 285: C268–C276, 2003.
19. Hegyi P, Rakonczay Z Jr, Gray MA, Argent BE. Measurement of
intracellular pH in pancreatic duct cells: a new method for calibrating the
fluorescence data. Pancreas 28: 427–434, 2004.
G202 URSODEOXYCHOLIC ACID IN ACUTE PANCREATITIS
AJP-Gastrointest Liver Physiol • doi:10.1152/ajpgi.00317.2015 • www.ajpgi.org
20. Hegyi P, Rakonczay Z Jr, Tiszlavicz L, Varro A, Toth A, Racz G,
Varga G, Gray MA, Argent BE. Protein kinase C mediates the inhibitory
effect of substance P on HCO3 secretion from guinea pig pancreatic ducts.
Am J Physiol Cell Physiol 288: C1030–C1041, 2005.
21. Ikegami T, Matsuzaki Y, Fukushima S, Shoda J, Olivier JL, Bousca-
rel B, Tanaka N. Suppressive effect of ursodeoxycholic acid on type IIA
phospholipase A2 expression in HepG2 cells. Hepatology 41: 896–905,
2005.
22. Im E, Akare S, Powell A, Martinez JD. Ursodeoxycholic acid can
suppress deoxycholic acid-induced apoptosis by stimulating Akt/PKB-
dependent survival signaling. Nutr Cancer 51: 110–116, 2005.
23. Kim JY, Kim KH, Lee JA, Namkung W, Sun AQ, Ananthanarayanan
M, Suchy FJ, Shin DM, Muallem S, Lee MG. Transporter-mediated bile
acid uptake causes Ca2-dependent cell death in rat pancreatic acinar
cells. Gastroenterology 122: 1941–1953, 2002.
24. Kowal JM, Haanes KA, Christensen NM, Novak I. Bile acid effects are
mediated by ATP release and purinergic signalling in exocrine pancreatic
cells. Cell Commun Signal 13: 28, 2015.
25. Kruger B, Albrecht E, Lerch MM. The role of intracellular calcium
signaling in premature protease activation and the onset of pancreatitis.
Am J Pathol 157: 43–50, 2000.
26. Lee HI, Choi CI, Sa JH, Lee YJ, Bae JW, Jang CG, Lee SY.
Ursodeoxycholic acid, an inhibitor of hepatocyte nuclear factor 1, did not
increase the systemic exposure of pitavastatin. Int J Clin Pharmacol Ther
52: 981–985, 2014.
27. Lemasters JJ, Nieminen AL, Qian T, Trost LC, Elmore SP,
Nishimura Y, Crowe RA, Cascio WE, Bradham CA, Brenner DA,
Herman B. The mitochondrial permeability transition in cell death: a
common mechanism in necrosis, apoptosis and autophagy. Biochim Bio-
phys Acta 1366: 177–196, 1998.
28. Lemasters JJ, Qian T, Bradham CA, Brenner DA, Cascio WE, Trost
LC, Nishimura Y, Nieminen AL, Herman B. Mitochondrial dysfunction
in the pathogenesis of necrotic and apoptotic cell death. J Bioenerg
Biomembr 31: 305–319, 1999.
29. Maleth J, Venglovecz V, Razga Z, Tiszlavicz L, Rakonczay Z Jr,
Hegyi P. Non-conjugated chenodeoxycholate induces severe mitochon-
drial damage and inhibits bicarbonate transport in pancreatic duct cells.
Gut 60: 136–138, 2011.
30. Marschall HU, Roeb E, Yildiz Y, Busch N, Nguyen H, Purucker E,
Thomas HG, Matern S. Study of human isoursodeoxycholic acid me-
tabolism. J Hepatol 26: 863–870, 1997.
31. Mithofer K, Fernandez-del Castillo C, Frick TW, Lewandrowski KB,
Rattner DW, Warshaw AL. Acute hypercalcemia causes acute pancre-
atitis and ectopic trypsinogen activation in the rat. Gastroenterology 109:
239–246, 1995.
32. Pallagi-Kunstar E, Farkas K, Maleth J, Rakonczay Z Jr, Nagy F,
Molnar T, Szepes Z, Venglovecz V, Lonovics J, Razga Z, Wittmann T,
Hegyi P. Bile acids inhibit Na/H exchanger and Cl/HCO3 exchanger
activities via cellular energy breakdown and Ca2 overload in human
colonic crypts. Pflügers Arch 467: 1277–1290, 2015.
33. Pallagi P, Balla Z, Singh AK, Dosa S, Ivanyi B, Kukor Z, Toth A,
Riederer B, Liu Y, Engelhardt R, Jarmay K, Szabo A, Janovszky A,
Perides G, Venglovecz V, Maleth J, Wittmann T, Takacs T, Gray MA,
Gacser A, Hegyi P, Seidler U, Rakonczay Z Jr. The role of pancreatic
ductal secretion in protection against acute pancreatitis in mice. Crit Care
Med 42: e177–e188, 2014.
34. Pandol SJ, Saluja AK, Imrie CW, Banks PA. Acute pancreatitis: bench
to the bedside. Gastroenterology 132: 1127–1151, 2007.
35. Perides G, van Acker GJ, Laukkarinen JM, Steer ML. Experimental
acute biliary pancreatitis induced by retrograde infusion of bile acids into
the mouse pancreatic duct. Nat Prot 5: 335–341, 2010.
36. Poupon RE, Poupon R, Balkau B. Ursodiol for the long-term treatment
of primary biliary cirrhosis. The UDCA-PBC Study Group. N Engl J Med
330: 1342–1347, 1994.
37. Pusl T, Vennegeerts T, Wimmer R, Denk GU, Beuers U, Rust C.
Tauroursodeoxycholic acid reduces bile acid-induced apoptosis by
modulation of AP-1. Biochem Biophys Res Commun 367: 208 –212,
2008.
38. Raraty M, Ward J, Erdemli G, Vaillant C, Neoptolemos JP, Sutton R,
Petersen OH. Calcium-dependent enzyme activation and vacuole forma-
tion in the apical granular region of pancreatic acinar cells. Proc Natl Acad
Sci USA 97: 13, 126–13, 131, 2000.
39. Reber HA, Mosley JG. The effect of bile salts on the pancreatic duct
mucosal barrier. Brit J Surg 67: 59–62, 1980.
40. Roda A, Hrelia P, Paolini M, Calzolari M, Grigolo B, Simoni P, Aldini
R, Forti GC. Pharmacokinetics of ursodeoxycholic acid in rat. Pharmacol
Res 23: 327–335, 1991.
41. Rodrigues CM, Fan G, Ma X, Kren BT, Steer CJ. A novel role for
ursodeoxycholic acid in inhibiting apoptosis by modulating mitochondrial
membrane perturbation. J Clin Invest 101: 2790–2799, 1998.
42. Rodrigues CM, Fan G, Wong PY, Kren BT, Steer CJ. Ursodeoxycholic
acid may inhibit deoxycholic acid-induced apoptosis by modulating mi-
tochondrial transmembrane potential and reactive oxygen species produc-
tion. Mol Med 4: 165–178, 1998.
43. Rodrigues CM, Ma X, Linehan-Stieers C, Fan G, Kren BT, Steer CJ.
Ursodeoxycholic acid prevents cytochrome c release in apoptosis by
inhibiting mitochondrial membrane depolarization and channel formation.
Cell Death Differ 6: 842–854, 1999.
44. Rolo AP, Oliveira PJ, Moreno AJ, Palmeira CM. Chenodeoxycholate
induction of mitochondrial permeability transition pore is associated with
increased membrane fluidity and cytochrome c release: protective role of
carvedilol. Mitochondrion 2: 305–311, 2003.
45. Rolo AP, Oliveira PJ, Moreno AJ, Palmeira CM. Chenodeoxycholate is
a potent inducer of the permeability transition pore in rat liver mitochon-
dria. Biosci Rep 21: 73–80, 2001.
46. Ros E, Navarro S, Bru C, Garcia-Puges A, Valderrama R. Occult
microlithiasis in ‘idiopathic’ acute pancreatitis: prevention of relapses by
cholecystectomy or ursodeoxycholic acid therapy. Gastroenterology 101:
1701–1709, 1991.
47. Rust C, Beuers U. Medical treatment of primary biliary cirrhosis and
primary sclerosing cholangitis. Clin Rev Allergy Immunol 28: 135–145,
2005.
48. Saeki T, Yui S, Hirai T, Fujii T, Okada S, Kanamoto R. Ursodeoxy-
cholic acid protects colon cancer HCT116 cells from deoxycholic acid-
induced apoptosis by inhibiting apoptosome formation. Nutr Cancer 64:
617–626, 2012.
49. Scheele GA, Fukuoka SI, Kern HF, Freedman SD. Pancreatic dysfunc-
tion in cystic fibrosis occurs as a result of impairments in luminal pH,
apical trafficking of zymogen granule membranes, and solubilization of
secretory enzymes. Pancreas 12: 1–9, 1996.
50. Schoemaker MH, Conde de la Rosa L, Buist-Homan M, Vrenken TE,
Havinga R, Poelstra K, Haisma HJ, Jansen PL, Moshage H. Taurour-
sodeoxycholic acid protects rat hepatocytes from bile acid-induced apo-
ptosis via activation of survival pathways. Hepatology 39: 1563–1573,
2004.
51. Sola S, Castro RE, Kren BT, Steer CJ, Rodrigues CM. Modulation of
nuclear steroid receptors by ursodeoxycholic acid inhibits TGF-beta1-
induced E2F-1/p53-mediated apoptosis of rat hepatocytes. Biochemistry
43: 8429–8438, 2004.
52. Sola S, Ma X, Castro RE, Kren BT, Steer CJ, Rodrigues CM.
Ursodeoxycholic acid modulates E2F-1 and p53 expression through a
caspase-independent mechanism in transforming growth factor 1-
induced apoptosis of rat hepatocytes. J Biol Chem 278: 48, 831– 48,
838, 2003.
53. Sun W, Watanabe Y, Toki A, Wang ZQ. Beneficial effects of hydro-
cortisone in induced acute pancreatitis of rats. Chin Med J 120: 1757–
1761, 2007.
54. Sun W, Watanabe Y, Wang ZQ. Expression and significance of ICAM-1
and its counter receptors LFA-1 and Mac-1 in experimental acute pancre-
atitis of rats. World J Gastroenterol 12: 5005–5009, 2006.
55. Testoni PA, Caporuscio S, Bagnolo F, Lella F. Idiopathic recurrent
pancreatitis: long-term results after ERCP, endoscopic sphincterotomy,
or ursodeoxycholic acid treatment. Am J Gastroenterol 95: 1702–1707,
2000.
56. Thomas JA, Buchsbaum RN, Zimniak A, Racker E. Intracellular pH
measurements in Ehrlich ascites tumor cells utilizing spectroscopic probes
generated in situ. Biochemistry 18: 2210–2218, 1979.
57. Thomson AB, Keelan M. Feeding rats diets containing cheno- or ursode-
oxycholic acid or cholestyramine modifies intestinal uptake of glucose and
lipids. Digestion 38: 160–170, 1987.
58. Thorn P, Lawrie AM, Smith PM, Gallacher DV, Petersen OH. Ca2
oscillations in pancreatic acinar cells: spatiotemporal relationships and
functional implications. Cell Calcium 14: 746–757, 1993.
59. Venglovecz V, Rakonczay Z Jr, Ozsvari B, Takacs T, Lonovics J, Varro
A, Gray MA, Argent BE, Hegyi P. Effects of bile acids on pancreatic ductal
bicarbonate secretion in guinea pig. Gut 57: 1102–1112, 2008.
60. Venneman NG, vanBerge-Henegouwen GP, van Erpecum KJ. Phar-
macological manipulation of biliary water and lipids: potential conse-
G203URSODEOXYCHOLIC ACID IN ACUTE PANCREATITIS
AJP-Gastrointest Liver Physiol • doi:10.1152/ajpgi.00317.2015 • www.ajpgi.org
quences for prevention of acute biliary pancreatitis. Curr Drug Targets 5:
193–198, 2005.
61. Voronina S, Longbottom R, Sutton R, Petersen OH, Tepikin A. Bile
acids induce calcium signals in mouse pancreatic acinar cells: implications
for bile-induced pancreatic pathology. J Physiol 540: 49–55, 2002.
62. Voronina SG, Barrow SL, Gerasimenko OV, Petersen OH, Tepikin
AV. Effects of secretagogues and bile acids on mitochondrial mem-
brane potential of pancreatic acinar cells: comparison of different
modes of evaluating DeltaPsim. J Biol Chem 279: 27, 327–27, 338,
2004.
63. Voronina SG, Barrow SL, Simpson AW, Gerasimenko OV, da Silva
Xavier G, Rutter GA, Petersen OH, Tepikin AV. Dynamic changes in
cytosolic and mitochondrial ATP levels in pancreatic acinar cells. Gas-
troenterology 138: 1976–1987, 2010.
64. Wan MH, Huang W, Latawiec D, Jiang K, Booth DM, Elliott V,
Mukherjee R, Xia Q. Review of experimental animal models of biliary
acute pancreatitis and recent advances in basic research. HPB (Oxford) 14:
73–81, 2012.
65. Woolbright BL, Jaeschke H. Novel insight into mechanisms of choles-
tatic liver injury. World J Gastroenterol 18: 4985–4993, 2012.
66. Yerushalmi B, Dahl R, Devereaux MW, Gumpricht E, Sokol RJ. Bile
acid-induced rat hepatocyte apoptosis is inhibited by antioxidants and
blockers of the mitochondrial permeability transition. Hepatology 33:
616–626, 2001.
G204 URSODEOXYCHOLIC ACID IN ACUTE PANCREATITIS
AJP-Gastrointest Liver Physiol • doi:10.1152/ajpgi.00317.2015 • www.ajpgi.org
